Description
| Description | MS417 is an inhibitor of BET-specific BRD4(BRD4-BD1 and BRD4-BD2 with IC50s of 30, 46 nM and Kds of 36.1, 25.4 nM, respectively), with weak selectivity at CBP BRD with IC50 of 32.7 μM. |
| Targets&IC50 | CBP BRD:32.7 μM, BRD4-BD2:46 nM , BRD4-BD1:30 nM |
| In vivo | BET (Bromodomain and Extra-Terminal domain)-specific bromodomain inhibitor MS417, designed to block BRD4 binding to the acetylated NF-κB, effectively attenuates NF-κB transcriptional activation of proinflammatory genes in kidney cells treated with TNFα or infected by HIV.?MS417 ameliorates inflammation and kidney injury in HIV-1 transgenic mice, an animal model for HIVAN[1]. |
| Synonyms | GTPL7512 |
| Molecular Weight |
414.91 |
| Formula | C20H19ClN4O2S |
| CAS No. | 916489-36-6 |
Storage
Powder: -20°C for 3 years
In solvent: -80°C for 2 years
Solubility Information
Ethanol: 50 mg/mL (120.51 mM),
Need ultrasonic
( < 1 mg/ml refers to the product slightly soluble or insoluble )
